From 2015-2020, we conducted the second study, a randomized, double-blind placebo-controlled multi-center efficacy trial of the same MUC1 vaccine in the setting of newly diagnosed advanced adenomas in 110 individuals (NCT-02134925) (15). Here, MUC1 is linked to adenoma.